{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:57:02Z","timestamp":1789394222033,"version":"build-2803163510"},"reference-count":41,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["156304)"],"award-info":[{"award-number":["156304)"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Autosomal recessive hypophosphatemic rickets (ARHR) are rare, heritable renal phosphate-wasting disorders that arise from overexpression of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23) leading to impaired bone mineralization (rickets and osteomalacia). Inactivating mutations of Dentin matrix protein 1 (DMP1) give rise to ARHR type 1 (ARHR1). Short stature, prominent bowing of the legs, fractures\/pseudofractures, and severe enthesopathy are prominent in this patient population. Traditionally, treatment consists of oral phosphate replacement and the addition of calcitriol but this approach is limited by modest efficacy and potential renal and gastrointestinal side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The advent of burosumab (Crysvita), a fully humanized monoclonal antibody to FGF23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, offers a unique opportunity to evaluate its safety and efficacy in patients with ARHR1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Monthly administration of burosumab to 2 brothers afflicted with the disorder resulted in normalization of serum phosphate, healing of pseudofracture, diminished fatigue, less bone pain, and reduced incapacity arising from the extensive enthesopathy and soft tissue fibrosis\/calcification that characterizes this disorder. No adverse effects were reported following burosumab administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present report highlights the beneficial biochemical and clinical outcomes associated with the use of burosumab in patients with ARHR1.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac433","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T23:08:47Z","timestamp":1658963327000},"page":"2777-2783","source":"Crossref","is-referenced-by-count":20,"title":["Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)"],"prefix":"10.1210","volume":"107","author":[{"given":"Xiuying","family":"Bai","sequence":"first","affiliation":[{"name":"Lady Davis Institute for Medical Research, CIUSSS de Centre-Ouest-de-l\u2019\u00eele-de-Montr\u00e9al, Jewish General Hospital, McGill University , Montr\u00e9al, Quebec, H3T 1E2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levental","sequence":"additional","affiliation":[{"name":"Department of Radiology, CIUSSS de Centre-Ouest-de-l\u2019\u00eele-de-Montr\u00e9al, Jewish General Hospital, McGill University , Montr\u00e9al, Quebec, H3T 1E2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-8161","authenticated-orcid":false,"given":"Andrew C","family":"Karaplis","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, CIUSSS de Centre-Ouest-de-l\u2019\u00eele-de-Montr\u00e9al, Jewish General Hospital, McGill University , Montr\u00e9al, Quebec, H3T 1E2 , Canada"},{"name":"Department of Medicine, Division of Endocrinology, CIUSSS de Centre-Ouest-de-l\u2019\u00eele-de-Montr\u00e9al, Jewish General Hospital, McGill University , Montr\u00e9al, Quebec, H3T 1E2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"issue":"11","key":"2022092808425063300_CIT0001","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneph.2010.121","article-title":"Hereditary disorders of renal phosphate wasting","volume":"6","author":"Alizadeh Naderi","year":"2010","journal-title":"Nat Rev Nephrol."},{"issue":"11","key":"2022092808425063300_CIT0002","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet."},{"issue":"3","key":"2022092808425063300_CIT0003","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1210\/en.2016-1642","article-title":"A mutation in the Dmp1 gene alters phosphate responsiveness in mice","volume":"158","author":"Ichikawa","year":"2017","journal-title":"Endocrinology."},{"key":"2022092808425063300_CIT0004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 actions on target tissues\u2014with and without klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2022092808425063300_CIT0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03008200390152061","article-title":"Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins","volume":"44","author":"Fisher","year":"2003","journal-title":"Connect Tissue Res."},{"issue":"1","key":"2022092808425063300_CIT0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"26","key":"2022092808425063300_CIT0007","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med."},{"issue":"4","key":"2022092808425063300_CIT0008","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022092808425063300_CIT0009","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022092808425063300_CIT0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-Linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int."},{"issue":"21","key":"2022092808425063300_CIT0011","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2022092808425063300_CIT0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10189","key":"2022092808425063300_CIT0013","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"2022092808425063300_CIT0014","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res."},{"key":"2022092808425063300_CIT0015","doi-asserted-by":"crossref","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone."},{"issue":"12","key":"2022092808425063300_CIT0016","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1210\/en.2012-1551","article-title":"Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice","volume":"153","author":"Karaplis","year":"2012","journal-title":"Endocrinology."},{"issue":"2","key":"2022092808425063300_CIT0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2008.10.040","article-title":"Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets","volume":"44","author":"Farrow","year":"2009","journal-title":"Bone."},{"issue":"8386","key":"2022092808425063300_CIT0018","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(84)92506-6","article-title":"Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis","volume":"1","author":"Brown","year":"1984","journal-title":"Lancet."},{"issue":"1","key":"2022092808425063300_CIT0019","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun."},{"issue":"11","key":"2022092808425063300_CIT0020","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00467-010-1565-3","article-title":"FGF23 and the parathyroid glands","volume":"25","author":"Silver","year":"2010","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"2022092808425063300_CIT0021","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"2022092808425063300_CIT0022","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1359\/jbmr.2001.16.11.2017","article-title":"Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts","volume":"16","author":"Toyosawa","year":"2001","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2022092808425063300_CIT0023","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1096\/fj.201600473R","article-title":"Hypophosphatemia promotes lower rates of muscle ATP synthesis","volume":"30","author":"Pesta","year":"2016","journal-title":"FASEB J."},{"issue":"4","key":"2022092808425063300_CIT0024","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/clinchem\/39.4.648","article-title":"Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma","volume":"39","author":"Rosalki","year":"1993","journal-title":"Clin Chem."},{"issue":"7","key":"2022092808425063300_CIT0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"10","key":"2022092808425063300_CIT0026","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/jbmr.105","article-title":"Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation","volume":"25","author":"M\u00e4kitie","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2022092808425063300_CIT0027","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2022092808425063300_CIT0028","doi-asserted-by":"crossref","first-page":"580.e5","DOI":"10.1016\/j.wneu.2016.07.076","article-title":"Minimally invasive surgical management of thoracic ossification of the ligamentum flavum associated with X-linked hypophosphatemia","volume":"94","author":"Riccio","year":"2016","journal-title":"World Neurosurg."},{"issue":"7","key":"2022092808425063300_CIT0029","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5435\/JAAOS-22-07-420","article-title":"Surgical treatment for ossification of the posterior longitudinal ligament in the cervical spine","volume":"22","author":"An","year":"2014","journal-title":"J Am Acad Orthop Surg."},{"issue":"2","key":"2022092808425063300_CIT0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.11005\/jbm.2014.21.2.127","article-title":"Genetics of ossification of the posterior longitudinal ligament of the spine: a mini review","volume":"21","author":"Ikegawa","year":"2014","journal-title":"J Bone Metab"},{"issue":"1","key":"2022092808425063300_CIT0031","article-title":"Serum periostin level reflects progression of ossification of the posterior longitudinal ligament","volume":"7","author":"Kawaguchi","year":"2022","journal-title":"JB JS Open Access."},{"issue":"6","key":"2022092808425063300_CIT0032","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1227\/01.NEU.0000215867.87770.73","article-title":"Ossification of the posterior longitudinal ligament: an update on its biology, epidemiology, and natural history","volume":"58","author":"Inamasu","year":"2006","journal-title":"Neurosurgery"},{"issue":"40","key":"2022092808425063300_CIT0033","doi-asserted-by":"crossref","first-page":"64649","DOI":"10.18632\/oncotarget.11623","article-title":"FGF23 promotes myocardial fibrosis in mice through activation of \u03b2-catenin","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget."},{"key":"2022092808425063300_CIT0034","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2017.09.009","article-title":"FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-\u03b2 autoinduction","volume":"92","author":"Smith","year":"2017","journal-title":"Int J Biochem Cell Biol."},{"issue":"18","key":"2022092808425063300_CIT0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184634","article-title":"FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis","volume":"20","author":"B\u00f6ckmann","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"12","key":"2022092808425063300_CIT0036","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120558","article-title":"Fibroblast growth factor 23 to alpha-klotho index correlates with systemic sclerosis activity: a proposal for novel disease activity marker","volume":"7","author":"Kotyla","year":"2018","journal-title":"J Clin Med."},{"issue":"3","key":"2022092808425063300_CIT0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","article-title":"Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice","volume":"85","author":"Liang","year":"2009","journal-title":"Calcif Tissue Int."},{"issue":"6","key":"2022092808425063300_CIT0038","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"issue":"1","key":"2022092808425063300_CIT0039","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1242\/dev.112714","article-title":"Enthesis fibrocartilage cells originate from a population of Hedgehog-responsive cells modulated by the loading environment","volume":"142","author":"Schwartz","year":"2015","journal-title":"Development."},{"issue":"4","key":"2022092808425063300_CIT0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cld.544","article-title":"Granulomas of the liver","volume":"7","author":"Culver","year":"2016","journal-title":"Clin Liver Dis (Hoboken)."},{"issue":"5","key":"2022092808425063300_CIT0041","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac433\/45207454\/dgac433.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/10\/2777\/46112856\/dgac433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/10\/2777\/46112856\/dgac433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:48:26Z","timestamp":1664354906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/10\/2777\/6650863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,9,28]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac433","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,7,27]]}}}